Cranberry
Vaccinium macrocarpon
Evidence Rating
C Moderate
Confidence Level
High
Traditions
Western
Last Updated
2/9/2026
Summary
Cranberry has the strongest clinical evidence of any urinary herb for UTI prevention, with the 2023 Cochrane update (50 studies, n=8,857) showing a significant 30% reduction in UTI risk (RR 0.70). The mechanism involves proanthocyanidin (PAC) Type A compounds that inhibit E. coli adhesion to urothelial cells. The 36mg/day PAC-A dose has emerged as a standardization target. Unlike most herbs in this collection, cranberry is primarily a North American tradition that has been adopted into European phytotherapy. EMA/HMPC and ESCOP have issued monographs, and it is increasingly recognized by conventional urologists worldwide as a legitimate preventive strategy.
⚠️
Drug Interactions
This herb has significant drug interactions. Do not use if you are taking medications without consulting a healthcare provider first. See detailed interaction information below.
Regulatory Status
| Regulatory Body | Status |
|---|---|
| Commission E (Germany) | ✓ Approved |
| ESCOP (European) | ✓ Approved |
| EMA/HMPC (EU) | ✓ Approved |
Metadata
| Field | Details |
|---|---|
| Common Names | Cranberry, American Cranberry, Large Cranberry (EN), Grossfruechtige Moosbeere / Kranbeere (DE) |
| Botanical Name | Vaccinium macrocarpon Aiton |
| Plant Family | Ericaceae (Heather family) |
| Part Used | Fruit (fructus) |
| Drug Name | Vaccinii macrocarpi fructus |
| Evidence Quality Rating | Strong |
Approved Indications
Commission E (Germany)
- No Commission E monograph (cranberry is not a traditional German medicinal plant; it is North American in origin)
ESCOP
- Published monograph: Vaccinii macrocarpi fructus (Cranberry)
- Prevention of recurrent uncomplicated lower urinary tract infections
EMA/HMPC
- Traditional Use: HMPC has developed an EU herbal monograph on Vaccinium macrocarpon fructus
- For mild, recurrent, lower urinary tract infections and burning on urination
- For prevention of recurrent uncomplicated lower urinary tract infections
- Assessment report and monograph in development/published through HMPC
Agreement/Disagreement
- Growing international consensus: Both European and US/Anglophone authorities increasingly recognize cranberry for UTI prevention
- ESCOP and HMPC support use for UTI prevention
- No Commission E monograph: Reflecting cranberry’s North American rather than Germanic origin
- US recognition: NCCIH acknowledges evidence for UTI prevention; American Urological Association and various clinical guidelines increasingly mention cranberry
- Cochrane 2023: Provides the strongest evidence base, significantly shifting the consensus toward supporting cranberry for UTI prevention
- This is the herb with the LEAST EU-US divergence — near-consensus across traditions
Conditions Treated
- Primary: Prevention of recurrent uncomplicated urinary tract infections
- Particularly effective in women with recurrent UTIs
- Also effective in children and in patients with susceptibility due to medical interventions (catheterization, surgery)
- Secondary: May reduce UTI symptoms (burning, frequency) during acute mild episodes
- NOT indicated for: Treatment of established acute UTI (not a substitute for antibiotics in active infection)
Mechanism of Action
Primary Mechanism: Anti-Adhesion
- Proanthocyanidins (PACs) Type A are the key active compounds
- PAC-A compounds bind to P-fimbriae of uropathogenic E. coli (UPEC)
- This prevents bacterial adhesion to urothelial cells lining the bladder
- Without attachment, bacteria are flushed out during normal urination
- This is a preventive mechanism (prevents colonization) rather than a bactericidal mechanism
Specificity of PAC Type
- PAC Type A (A-type proanthocyanidins): The active anti-adhesion compounds — these are relatively unusual in nature and are characteristic of cranberry
- PAC Type B: Common in many fruits (grapes, apples, chocolate) but do NOT have anti-adhesion activity against E. coli
- This distinction is critical for product standardization
Additional Mechanisms
- Urinary acidification: Cranberry acidifies urine, which may independently inhibit bacterial growth
- Hippuric acid: Cranberry converts quinic acid to hippuric acid in urine, which has mild bacteriostatic properties
- Fructose: D-mannose content may block bacterial adhesion (Type 1 fimbriae)
- Anti-biofilm activity: May inhibit E. coli biofilm formation
Key Bioactive Compounds
- Proanthocyanidins Type A (PAC-A): 1-2% of dried fruit; the primary active compounds
- Anthocyanins: Cyanidin, peonidin glycosides (antioxidant)
- Organic acids: Quinic acid, malic acid, citric acid (urinary acidification)
- D-Mannose: Anti-adhesion via Type 1 fimbriae blocking
- Phenolic acids: Benzoic acid, hydroxycinnamic acids
- Flavonols: Quercetin glycosides
Clinical Evidence Summary
Cochrane Systematic Review 2023 (Williams et al.)
- Landmark publication: The most authoritative evidence synthesis
- Scope: 50 RCTs, n=8,857 participants (update adds 26 new studies to previous review)
- Overall finding: Cranberry products reduce UTI risk by 30% (RR 0.70, 95% CI 0.58-0.84; moderate certainty)
Subgroup Results:
| Population | Studies | Participants | Risk Ratio | Certainty |
|---|---|---|---|---|
| Women with recurrent UTI | 8 | 1,555 | 0.74 (0.55-0.99) | Moderate |
| Children | 5 | 504 | 0.46 (0.32-0.68) | Moderate |
| Susceptibility from intervention | 6 | 1,434 | 0.47 (0.37-0.61) | Moderate |
| Pregnant women | 2 | 781 | 0.89 (0.58-1.35) | Low |
| Elderly | 5 | 1,326 | 0.82 (0.56-1.21) | Low |
| People with neurogenic bladder | 2 | 337 | 0.78 (0.46-1.31) | Low |
PAC Dose-Response Evidence
Meta-analysis: High-Dose PAC (Frontiers in Nutrition, 2024)
- When daily PAC intake was at least 36mg, UTI risk reduced by 18%
- 10 RCTs analyzed
- Supports the 36mg/day threshold as minimum effective dose
PACCANN Trial (UK)
- Standardized high-dose vs. low-dose cranberry PAC extract
- Comparing 72mg PAC vs. 36mg PAC for prevention of recurrent UTI
- Protocol published; results awaited [NEEDS-RESEARCH]
Key dosing insight
- PAC-A at 36mg/day produces urine with documented anti-adhesive properties in ex vivo assays
- However, the Cochrane review found no clear dose-response relationship between PAC dose categories
Recent Major Trial (AJCN, 2025)
- Whole cranberry fruit powder supplement
- 6-month multicenter, randomized, double-blind, placebo-controlled trial
- Reduced incidence of culture-confirmed UTIs in females with history of recurrent UTI
- [Source: American Journal of Clinical Nutrition, 2025]
Evolution of Evidence
| Year | Cochrane Finding | Recommendation |
|---|---|---|
| 2004 | Some evidence of benefit | May be helpful |
| 2008 | Evidence supports efficacy | Recommended for women |
| 2012 | Benefit less clear than previously thought | Insufficient evidence |
| 2023 | Moderate certainty of 30% risk reduction | Supports use for prevention |
The 2012 negative update led to years of skepticism; the 2023 update with 26 additional studies rehabilitated cranberry’s evidence base.
European vs US/Anglophone Consensus
| Aspect | European Position | US/Anglophone Position |
|---|---|---|
| Origin | Adopted from North America | Native tradition |
| Regulatory status | ESCOP monograph; HMPC traditional use monograph | Dietary supplement (no FDA drug approval) |
| Clinical acceptance | Increasingly accepted by urologists | Widely accepted; included in some clinical guidelines |
| Prescribing habits | Growing use; less traditional than goldenrod/bearberry | Very commonly recommended by physicians and pharmacists |
| Products | Various capsules, juices | Ocean Spray, various supplements |
Unique status: Unlike other herbs in this collection, cranberry shows CONVERGENCE rather than divergence between EU and US traditions. Both are moving toward acceptance for UTI prevention.
Safety Profile
Contraindications
- Known hypersensitivity to Vaccinium species
- History of kidney stones (oxalate type) — cranberry may increase urinary oxalate excretion [CONTESTED — evidence is mixed]
- Caution in patients on warfarin (see drug interactions)
Drug Interactions
- Warfarin: Potential interaction; case reports of increased INR with cranberry juice. Mechanism may involve CYP2C9 inhibition. Clinical significance is debated — most systematic analyses suggest the interaction is clinically insignificant at normal cranberry doses, but monitoring is prudent
- Tacrolimus: Case reports of interaction; monitor levels
- Proton pump inhibitors: May reduce absorption of acid-dependent drugs (cranberry acidifies urine/GI tract)
- Urinary alkalinizers / bearberry: Cranberry’s acidification antagonizes bearberry’s alkaline-dependent mechanism — do NOT use together
Side Effects
- Common: GI discomfort (nausea, diarrhea) — especially with juice (due to acidity and sugar content)
- Uncommon: Increased urinary oxalate excretion
- Rare: Allergic reactions
- Overall: Excellent safety profile; cranberry juice and supplements are widely consumed with minimal adverse effects
Pregnancy/Lactation
- Generally considered safe in food amounts
- Cranberry supplements: Insufficient data for definitive safety in pregnancy
- Cochrane 2023 included 2 studies in pregnant women (n=781) without safety concerns noted
- Likely safe but standard precautionary language applies
Clinical Dosage
Standardized Dosage Forms
| Form | Dosage | Notes |
|---|---|---|
| Cranberry juice (unsweetened) | 200-750ml daily | Compliance often poor (taste, calories); must be actual cranberry, not cocktail |
| Cranberry extract capsules | Standardized to 36mg PAC-A/day (minimum) | Most practical form for long-term prevention |
| Whole cranberry fruit powder | 500mg daily | Studied in recent AJCN trial |
| Dried cranberries | 42g dried fruit daily | Used in some studies |
PAC Standardization Target
- 36mg PAC-A per day: The emerging consensus minimum effective dose
- 72mg PAC-A per day: Under study as potentially more effective (PACCANN trial)
- Products should be standardized to PAC-A content (Type A proanthocyanidins specifically)
- Caution: Many commercial products use total PAC or DMAC method values that may overestimate PAC-A content
Key Products
- Cran-Max (US): Whole cranberry concentrate; widely used in clinical trials
- Ellura (UK/EU): 36mg PAC-A standardized capsules
- UTI-STAT (US): Cranberry supplement
- Various juice products: Ocean Spray, etc. (variable PAC content; high sugar in sweetened versions)
Duration of Treatment
- Preventive use: Long-term (months to years); no maximum duration established
- Continuous daily use required for ongoing prevention
- Effect ceases when supplementation stops
Sources
- Cochrane Review 2023 — Cranberries for Preventing UTIs
- Cochrane Review 2023 (PubMed)
- Cochrane Review 2023 (PMC)
- High-Dose PAC Meta-analysis (PMC)
- High-Dose PAC Meta-analysis (Frontiers in Nutrition)
- EMA/HMPC Assessment on Vaccinium macrocarpon
- ESCOP Monograph — Cranberry
- AJCN 2025 — Cranberry Powder for Recurrent UTI
- High vs Low Dose PAC RCT (BMC Urology)
- Altmeyers Encyclopedia — Vaccinii macrocarpon fructus
Connections
- See Bearberry Uva Ursi for the contrasting UTI treatment herb (pH mechanisms are OPPOSITE; do NOT combine)
- See Goldenrod for supportive irrigation therapy that can be combined with cranberry